Voya Investment Management LLC Purchases 282,521 Shares of Haemonetics Co. (NYSE:HAE)

Voya Investment Management LLC grew its position in Haemonetics Co. (NYSE:HAE) by 820.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 316,952 shares of the medical instruments supplier’s stock after purchasing an additional 282,521 shares during the quarter. Voya Investment Management LLC’s holdings in Haemonetics were worth $24,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Hood River Capital Management LLC lifted its stake in shares of Haemonetics by 6.8% during the 4th quarter. Hood River Capital Management LLC now owns 214,290 shares of the medical instruments supplier’s stock valued at $16,732,000 after buying an additional 13,710 shares in the last quarter. Pinebridge Investments L.P. lifted its position in shares of Haemonetics by 42.7% in the fourth quarter. Pinebridge Investments L.P. now owns 22,483 shares of the medical instruments supplier’s stock valued at $1,755,000 after acquiring an additional 6,727 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Haemonetics by 7.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 354,281 shares of the medical instruments supplier’s stock worth $27,664,000 after acquiring an additional 25,617 shares during the period. Dark Forest Capital Management LP purchased a new stake in shares of Haemonetics during the fourth quarter worth about $369,000. Finally, Stifel Financial Corp raised its stake in Haemonetics by 7.3% during the 4th quarter. Stifel Financial Corp now owns 14,776 shares of the medical instruments supplier’s stock valued at $1,154,000 after purchasing an additional 1,006 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HAE shares. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $95.00 to $68.00 in a report on Friday, February 7th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC decreased their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. Raymond James restated a “strong-buy” rating and set a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Trading Up 1.0 %

Shares of NYSE HAE opened at $62.53 on Friday. The stock has a market capitalization of $3.14 billion, a P/E ratio of 24.62, a PEG ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $97.97. The business’s 50 day moving average is $62.83 and its two-hundred day moving average is $72.13. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.